FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 1996 EDITEK, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-11394 95-3863205 (Commission File Number) (IRS Employer Identification No.) 1238 Anthony Road Burlington, North Carolina 27215 (Address of principal executive offices) (Zip Code) (910) 226-6311 (Registrant's telephone number, including area code) Item 5. Other Events. On March 7, 1996, the Registrant announced today that it will consolidate all laboratory testing services into the recently acquired MEDTOX laboratory in St. Paul, Minnesota. The laboratory services in New Jersey will be discontinued and sample testing will be transitioned to MEDTOX during the next four weeks. The Company will maintain client services, the courier network and certain sales/administrative functions in a reduced New Jersey facility. A comprehensive program has been implemented to ensure a smooth conversion. As a result of this consolidation of laboratory operations, EDITEK will take a one time charge against the operating results for 1995 of approximately $3.8 million or $0.41 per share. This charge is primarily for a write-off of goodwill of approximately $3.1 million associated with the acquisition of PDLA and for expected restructuring costs of approximately $700,000. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EDITEK, INC. Date: March 11, 1996 By: /s/ Peter J. Heath 					Name: Peter J. Heath 					Title:	Vice President of Finance and Chief Financial Officer